SCHEMBL7686514

SCHEMBL7686514

CC(C)(C)OC(=O)N1CCC[C@H](CCCBr)C1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GLS O94925 2/20 0.51
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
BACE1 P56817 2/20 0.47
CTSD P07339 1/20 0.47
FPR3 P25089 1/20 0.45
FPR2 P25090 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
ACKR3 P25106 1/20 0.44
NR1H2 P55055 1/20 0.43
KDM1A O60341 1/20 0.42
FEN1 P39748 1/20 0.42
SCN9A Q15858 1/20 0.42
GPR119 Q8TDV5 3/20 0.41
FAAH O00519 1/20 0.41
CHEK2 O96017 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7686804 1.00 GLS (0.51) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL6959152 1.00 GLS (0.51) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL7692869 0.95 GLS (0.49) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL11980483 0.92 GPR119 (0.48) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL7685622 0.92 MEN1 (0.52) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL7691100 0.92 MEN1 (0.52) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL758457 0.92 MEN1 (0.52) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL20310041 0.88 MEN1 (0.51) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL1070437 0.88 MEN1 (0.51) GLSMEN1ALDH1A1MAPTKMT2A
SCHEMBL8555556 0.88 MEN1 (0.51) GLSMEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists BRITTON THOMAS CHARLES (US) 2002-01-17 US disclosed
US-6255494-B1 SUBSTITUTED BENZIMIDAZOLES USEFUL IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y (AROUND ARTERIES IN HEART, RESPIRATORY TRACT, GASTROINTESTINAL TRACT AND GENITOURINARY TRACT); ETIOLOGY OF PSYCHIATRIC DISORDERS ELI LILLY AND COMPANY 2001-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020007071-A1 Benzimidzolyl neuropeptide Y receptor antagonists NPY1R, NPY2R, NPY5R GLS 728/4885MEN1 815/4885ALDH1A1 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.